Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Net Margin: 2014-2025

Historic Net Margin for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to 29.29%.

  • Ascendis Pharma A's Net Margin fell 14224.00% to 29.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.59%, marking a year-over-year decrease of 5268.00%. This contributed to the annual value of -103.97% for FY2024, which is 7654.00% up from last year.
  • Per Ascendis Pharma A's latest filing, its Net Margin stood at 29.29% for Q3 2025, which was up 14.98% from 25.47% recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Net Margin peaked at 1,332.40% during Q2 2022, and registered a low of -13,148.14% during Q2 2021.
  • For the 3-year period, Ascendis Pharma A's Net Margin averaged around 145.72%, with its median value being 136.65% (2024).
  • Over the last 5 years, Ascendis Pharma A's Net Margin had its largest YoY gain of 2,378,349bps in 2021, and its largest YoY loss of 652,704bps in 2021.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Net Margin stood at -2,165.86% in 2021, then skyrocketed by 125,990bps to -905.96% in 2022, then spiked by 84,178bps to -64.18% in 2023, then spiked by 4,206bps to -22.12% in 2024, then crashed by 14,224bps to 29.29% in 2025.
  • Its last three reported values are 29.29% in Q3 2025, 25.47% for Q2 2025, and 93.81% during Q1 2025.